Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.023
Buy
RSI(14)
52.252
Neutral
STOCH(KDJ)(9,3,3)
45.042
Sell
ATR(14)
0.236
Low Volatility
CCI(14)
16.527
Neutral
Williams %R
32.990
Buy
TRIX(12,20)
0.110
Sell
StochRSI(14)
21.840
Sell
Grifols SA
GRFS9.280USD
+0.090+0.98%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
2.39BMarket Cap
15.27P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Grifols SA
Currency: USD Updated: 2026-02-06Key Insights
Grifols SA's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 71 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.20.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Grifols SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Grifols SA Highlights
StrengthsRisks
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 22.33% year-on-year.
Undervalued
The company’s latest PE is 15.27, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 145.03M shares, decreasing 11.86% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 1.94K shares of this stock.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
12.200
Target Price
+32.75%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Grifols SA is 8.88, ranking 31 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 2.18B, representing a year-over-year increase of 10.68%, while its net profit experienced a year-over-year increase of 161.30%.
Score
Financials
5.96
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
9.68
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
8.78
Grifols SA's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Grifols SA is 5.38, ranking 148 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 15.27, which is 846.11% below the recent high of 144.48 and 4757.31% above the recent low of -711.21.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 71/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Grifols SA is 7.00, ranking 118 out of 159 in the Pharmaceuticals industry. The average price target is 12.20, with a high of 12.20 and a low of 12.20.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
12.200
Target Price
+32.75%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
Grifols SA
GRFS
8
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Grifols SA is 7.00, ranking 89 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 9.71 and the support level at 8.74, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
9.366
Sell
MA10
9.305
Sell
MA20
9.172
Buy
MA50
9.083
Buy
MA100
9.202
Buy
MA200
9.162
Buy
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Grifols SA is 5.00, ranking 73 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 56.34%, representing a quarter-over-quarter decrease of 3.84%. The largest institutional shareholder is Brandes Investmen, holding a total of 29.12M shares, representing 11.31% of shares outstanding, with 13.45% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Capital World Investors
Permian Investment Partners, LP
Black Creek Investment Management, Inc.
Millennium Management LLC
BofA Global Research (US)
Janus Henderson Investors
BMO Capital Markets (US)
Arrowstreet Capital, Limited Partnership
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Grifols SA is 7.30, ranking 38 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.67. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.67
VaR
+4.26%
240-Day Maximum Drawdown
+25.49%
240-Day Volatility
+42.72%
Return
Best Daily Return
60 days
+4.52%
120 days
+4.52%
5 years
+24.78%
Worst Daily Return
60 days
-3.67%
120 days
-6.40%
5 years
-21.83%
Sharpe Ratio
60 days
+1.52
120 days
-0.93
5 years
-0.03
Risk Assessment
Maximum Drawdown
240 days
+25.49%
3 years
+52.68%
5 years
+71.12%
Return-to-Drawdown Ratio
240 days
+0.98
3 years
+0.22
5 years
-0.14
Skewness
240 days
+0.27
3 years
+0.09
5 years
+0.18
Volatility
Realised Volatility
240 days
+42.72%
5 years
+56.88%
Standardised True Range
240 days
+3.06%
5 years
+3.89%
Downside Risk-Adjusted Return
120 days
-133.83%
240 days
-133.83%
Maximum Daily Upside Volatility
60 days
+21.82%
Maximum Daily Downside Volatility
60 days
+33.11%
Liquidity
Average Turnover Rate
60 days
+0.14%
120 days
+0.14%
5 years
--
Turnover Deviation
20 days
-30.63%
60 days
-29.10%
120 days
-29.62%
Peer Comparison
Pharmaceuticals
Grifols SA
GRFS
7.06 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
9.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.92 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
